Related Experiment Videos
[Ambroxol versus betamethasone for stimulating antepartal lung maturity--a multicenter study]
Zeitschrift Fur Geburtshilfe Und Perinatologie
|February 1, 1986
Summary
Ambroxol and Betamethasone were compared for preventing respiratory distress syndrome (RDS) in premature infants. Both drugs showed similar effectiveness, suggesting Ambroxol is a viable alternative to Betamethasone for RDS prevention.
Area of Science:
- Neonatal Medicine
- Pharmacology
Background:
- Respiratory distress syndrome (RDS) is a significant concern in premature infants.
- Prenatal corticosteroid therapy, like Betamethasone, is standard for RDS prevention.
- Alternative agents are sought due to potential corticosteroid side effects.
Purpose of the Study:
- To compare the efficacy of Ambroxol and Betamethasone in preventing neonatal RDS.
- To evaluate Ambroxol as a potential alternative to corticosteroids for prenatal RDS prevention.
Main Methods:
- A multicenter, randomized, double-blind study involving 185 patients between 28-36 weeks gestation.
- Patients received either Ambroxol or Betamethasone for prenatal RDS prevention.
- RDS morbidity was assessed using standardized clinical, radiological, and blood-gas analyses.
Main Results:
- RDS morbidity was 9% in the Ambroxol group (7/79) and 6% in the Betamethasone group (5/86), a statistically insignificant difference.
- Amniotic fluid surfactant parameters increased post-therapy in both groups without significant inter-group differences.
- Patient demographics and delivery characteristics were comparable between the treatment groups.
Conclusions:
- Ambroxol demonstrated comparable efficacy to Betamethasone in preventing neonatal respiratory distress syndrome.
- Ambroxol can be considered an effective alternative to Betamethasone for prenatal RDS prevention, potentially avoiding corticosteroid-related concerns.